The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Petrukhin A.S.

Kafedra nervnykh bolezneĭ pediatricheskogo fakul'teta s kursom fakul'teta usovershenstvovaniia vracheĭ Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

Pylaeva O.A.

Kafedra nervnykh bolezneĭ pediatricheskogo fakul'teta s kursom fakul'teta usovershenstvovaniia vracheĭ Rossiĭskogo gosudarstvennogo meditsinskogo universiteta

Cerebrolysin in pediatric neurology practice

Authors:

Petrukhin A.S., Pylaeva O.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2014;114(1‑2): 75‑80

Read: 2823 times

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Petrukhin AS, Pylaeva OA. Cerebrolysin in pediatric neurology practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2014;114(1‑2):75‑80. (In Russ.)

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Therapy prospects for post-stroke apha­sia. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;(4-2):86-91
Cere­brolysin with repe­rfusion therapy in ischemic stroke: a prospective analysis of multimodal brain imaging data from the CERE­HETIS trial. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):84-98
A clinical case of treating a patient with severe ischemic stroke and cancer. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):114-117
Expe­rience of using of Cere­brolysin in comprehensive reha­bilitation of a patient after ischemic stroke with motor defi­cit and apha­sia. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;(1):101-105
The effect of Cere­brolysin on the deve­lopment of skills in patients after acute cere­brovascular acci­dents. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;(2):32-38
The effect of neuroprotectors on the level of BDNF, tumor necrosis factor alpha and apoptosis markers, and in acute cere­brovascular acci­dents. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;(2):123-129
Abstract:

Objective. To analyze the possibility of using MMSE and CGIS as well as the Clock drawing test for the objectification of treatment efficacy in Alzheimer's disease (AD). Material and methods. Authors examined 765 patients with mild and moderate dementia treated with donepezil during 3 months. The efficacy was assessed using the MMSE and CGIS. Results and conclusion. The methods demonstrated the reproducibility compared to those used in earlier clinical trials and efficacy of donepezile in the treatment of mild and moderate AD, the Clock drawing test can be recommended as an additional technique for assessment of treatment efficacy in relation to opticospatial function.

Keywords:

cerebrolysin
diseases of the nervous system in children

Authors:

Petrukhin A.S.

Kafedra nervnykh bolezneĭ pediatricheskogo fakul'teta s kursom fakul'teta usovershenstvovaniia vracheĭ Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

Pylaeva O.A.

Kafedra nervnykh bolezneĭ pediatricheskogo fakul'teta s kursom fakul'teta usovershenstvovaniia vracheĭ Rossiĭskogo gosudarstvennogo meditsinskogo universiteta

Close metadata

References:

  1. Delrieu J., Piau A., Caillaud C. et al. Managing cognitive dysfunction through the continuum of Alzheimer's disease. Role of pharmacotherapy. CNS Drugs 2011; 25: 213-226.
  2. Gavrilova S.I. Dementsiya. V kn.: Rukovodstvo po geriatricheskoi psikhiatrii. Pod red. S.I. Gavrilovoi. M: Pul's 2014; 23-145.
  3. Schneider L.S. New therapeutic approaches to Alzheimer's disease. J Clin Psychiatry 1996; 57: 14: 30-36.
  4. Gavrilova S.I., Zharikov G.A. Sovremennye strategii patogeneticheskoi terapii bolezni Al'tsgeimera. Vestnik RAMN 2001; 7: 13-18.
  5. Yamanishi Y., Ogura H., Kosasa T. et al. Inhibitory action of E2020, a novel acetylcholinesterase inhibitor, on cholinesterase: comparison with other inhibitors. In: T. Nagatsu, A. Fisher, M. Yoshida (eds.). Basic, Clinical, and Therapeutic Aspects of Alzheimer's and Parkinson's Diseases. New York: Plenum Press 1990; 2: 409-413.
  6. Rogers S.L., Friedhoff L.T. and Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996; 7: 293-303.
  7. Rogers S.L., Farlow M.R., Doody R.S. et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998; 50: 136.
  8. Courtney C., Farrell D., Gray R. et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004; 363: 2105.
  9. Birks J.S., Harvey R. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2003; CD001190.
  10. Winblad B., Engedal K., Soininen H. et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489.
  11. Rockwood K., Graham J., Fay S. Goal setting and attainment in patients with Alzheimer's disease treated with donepezil. J Neurol Neurosurg Psychiaty 2002; 73: 500-507.
  12. Doody R.S., Geldmacher D.S., Gordon B. et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001; 58: 427.
  13. Mohs R.C., Doody R.S., Morris J.C. et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57: 481.
  14. Hernandez R.K., Farwell W., Cantor M.D., Lawler E.V. Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system. J Am Geriatr Soc 2009; 57: 1997.
  15. Kolykhalov I.V. Lechenie povedencheskikh i psikhopatologicheskikh rasstroistv u patsientov s bolezn'yu Al'tsgeimera. Sovremennaya terapiya v psikhiatrii i nevrologii 2013; 3: 15-23.
  16. Barak Y., Bodner E., Zemishlani H. et. al. Donepezil for the treatment of behavioral disturbances in Alzheimer's disease: a 6-month open trial. Arch Gerontol Geriatr 2001; 33: 237-241.
  17. Zharikov G.A., Kalyn Ya.B., Kolykhalov I.V., Mikhailova N.M., Selezneva N.D., Gavrilova S.I. Opyt primeneniya arisepta (donepezila) v lechenii bolezni Al'tsgeimera. Psikhiatriya 2003; 4: 34-40.
  18. Karpyuk V.A., Duduk S.L., Lelyavko I.A., Kolykhalov I.V., Gavrilova S.I. Izuchenie effektivnosti i bezopasnosti Alzepila (donepezila) dlya lecheniya bolezni Al'tsgeimera na stadii myagkoi i umerenno vyrazhennoi dementsii. Sovremennaya terapiya v psikhiatrii i nevrologii 2012; 3: 27-32.
  19. Boada-Rovira M., Brodaty H., Cras P., Baloyannis S., Emre M., Zhang R., Bahra R. 322 Study Group. Efficacy and safety of donepezil in patients with Alzheimer's disease: results of a global, multinational, clinical experience study. Drugs Aging 2004; 21: 1: 43-53.
  20. Mehta S., Chandersekhar K., Prasadrao G., Dutt L., Patkar S., Nagpal R.D., Gupta M., Raju G.S., Praveen K.K., Prasad B.S., Roy T., Kushwaha S., Nag J., Langade D., Pawar D. Safety and efficacy of donepezil hydrochloride in patients with mild to moderate Alzheimer's disease: Findings of an observational study. Indian J Psychiatry 2012; 54: 4: 337-343.
  21. Burns A., Rossor M., Hecker J., Gauthier S., Petit H., Möller H.J., Rogers S.L., Friedhoff L.T. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10: 3: 237-244.
  22. Nozawa M., Ichimiya Y., Nozawa E., Utumi Y., Sugiyama H., Murayama N., Iseki E., Arai H. Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan. Psychogeriatrics 2009; 9: 2: 50-55.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.